Paclitaxel-loaded stealth liposomes: Development, characterization, pharmacokinetics, and biodistribution
Source abstract
Abstract
AIM: In the present paper, paclitaxel (PTX)-loaded stealth liposomes were prepared with thin film hydration technique in order to prolong the time of circulation. METHOD: The liposomes' characterization, in vitro release, pharmacokinetics, and biodistribution profile of the drug were investigated. RESULTS: Microscope showed that the liposomes were spherical in shape with a smooth surface and the size was uniform and appropriate for administration via intravenous injection. The encapsulation efficiency was 91.1 ± 4.3%, and the mean diameter was 82.2 ± 7.6 nm from three batches. The results of in vivo studies indicated that PTX-loaded stealth liposomes show favorable pharmacokinetics and biodistribution compared to the free drug. In comparison with free PTX, the AUC0-t of PTX liposomes and stealth liposomes increased 1.91- and 3.39-fold, respectively. The stealth liposomes were long-circulating showing a half-life time of 34.2 h against 13.7 h for the conventional ones. CONCLUSIONS: These results suggest that stealth liposomes would serve as a potent PTX delivery vehicle for the future cancer chemotherapy and represent a suitable platform for the development of targeted liposomal PTX systems.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems · Lipid Membrane Structure and Behavior
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutical, 85 Hospital of People's Liberation Army, Shanghai, P. R. China
References (21)
Show source-provided references
1. 10.1016/j.biomaterials.2013.11.08810.1016/j.biomaterials.2013.11.088 ↗
2. 10.3109/0363904090309973610.3109/03639040903099736 ↗
3. 10.1016/S0168-3659(99)00166-210.1016/S0168-3659(99)00166-2 ↗
4. Dorr RT. · Ann Pharmacother · 1994 · 28 · 511
5. 10.1097/01.cad.0000167902.53039.5a10.1097/01.cad.0000167902.53039.5a ↗
6. 10.1007/BF0004746810.1007/BF00047468 ↗
7. Kramer I · Eur Hosp Pharm · 1995 · 1 · 37
8. Maeda H · Crit Rev Ther Drug Carrier Syst · 1989 · 6 · 193
9. 10.18632/oncotarget.190610.18632/oncotarget.1906 ↗
10. 10.1073/pnas.132413511110.1073/pnas.1324135111 ↗
11. 10.1080/0735790070122486210.1080/07357900701224862 ↗
12. 10.1016/0014-5793(96)00452-810.1016/0014-5793(96)00452-8 ↗
13. 10.3892/mmr.2013.126410.3892/mmr.2013.1264 ↗
14. 10.1021/ja00738a04510.1021/ja00738a045 ↗
15. 10.1200/JCO.1990.8.7.126310.1200/JCO.1990.8.7.1263 ↗
16. 10.1016/0304-4157(92)90038-C10.1016/0304-4157(92)90038-C ↗
17. 10.7314/APJCP.2013.14.4.259110.7314/APJCP.2013.14.4.2591 ↗
18. 10.1021/jf405675g10.1021/jf405675g ↗
19. 10.1016/j.fct.2012.11.00410.1016/j.fct.2012.11.004 ↗
20. Yuan F · Cancer Res · 1995 · 55 · 3752
21. 10.1016/j.lungcan.2012.01.00510.1016/j.lungcan.2012.01.005 ↗